Presatovir
Phase 2Small molecule
GileadPresatovir is one of 13 small molecule programs targeting Respiratory Syncytial Virus Infection. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Respiratory Syncytial Virus Infection
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Virazole
CConrado Roberto Hoffmann Filho
Approved
Fluzone
SanofiPhase 3
SYNAGIS
SSwedish Orphan Biovitrum
Phase 3
Lagevrio
Merck & Co.Phase 2
Aluminum Phosphate
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Ad26.rsv.pref
Johnson & JohnsonPhase 2
JNJ-53718678
Johnson & JohnsonPhase 2
Lumicitabine
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory Syncytial Virus (RSV) Infection3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Presatovir. EMBL-EBI & Wellcome Sanger Institute.
- [4]